Inotiv, Inc. (NOTVQ) vs ProPhase Labs, Inc. (PRPH)

Inotiv, Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. Inotiv, Inc. is the larger, with a market value of $2.8M against $1.2M — 2.4× the size. Inotiv, Inc. grew revenue faster over the last twelve months: 5.61% against −43.5%. Inotiv, Inc. has the higher net margin (−17.1% vs −717.4%) and the higher return on invested capital (−6.19% vs −387.3%). Across the 17 metrics below, Inotiv, Inc. leads on 13 and ProPhase Labs, Inc. on 4.

Valuation

Metric NOTVQ PRPH Diagnostics & Research median
P/E n/m n/m 33.95
P/S 0.00 0.04 4.87
P/B 0.00 n/m 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA 60.99 n/m 25.20
EV/Sales 1.57 1.84 5.66
Earnings yield (25,300.00%) (23,896.00%) (1.75%)
Free cash flow yield (2,858.05%) (3,945.49%) (0.13%)

Profitability

Metric NOTVQ PRPH Diagnostics & Research median
Gross margin 22.94% 16.38% 50.89%
Operating margin (9.48%) (498.73%) (8.57%)
Net margin (17.14%) (717.43%) (6.37%)
Free cash flow margin (1.95%) (175.22%) 0.00%
Return on equity (74.09%) (543.95%) (2.92%)
Return on assets (11.85%) (45.53%) (6.71%)
Return on invested capital (6.19%) (387.30%) 0.00%

Growth

Metric NOTVQ PRPH Diagnostics & Research median
Revenue growth (TTM) 5.61% (43.52%) 7.69%
EPS growth (last fiscal year) 49.64% 93.33% —
Revenue growth, 5-year CAGR 53.36% (21.43%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NOTVQ PRPH Diagnostics & Research median
Debt to equity 5.49 (1.82) 0.11
Current ratio 0.27 0.05 2.02
Net debt to EBITDA 12.68 (0.74) 0.78

Dividend

Metric NOTVQ PRPH Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric NOTVQ PRPH Diagnostics & Research median
Market cap 2.79m 1.17m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack